Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for KB111 (HSV-1 Gene Therapy) in Hailey-Hailey Disease. The expected timing is based on the latest available company guidance and may change.
11/03/25:- IND cleared for KB111 in HHD. 02/17/26:- FDA Fast Track; develop HHD scale by H1 2026; start registrational trial in H2 2026. 05/04/26:- FDA platform designation; HALITE-1 safety study starting; expect HALITE-1 results and FDA discussions in H2 2026. 08/03/26:- HALITE-1 dosing started; interim results before year-end; FDA meeting follows completion.
Verification
Confirm timing and program details against the company announcement or filing.